Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.

ABSTRACT:

Background

Abiraterone and enzalutamide are castration-resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets.

Methods

We used national Veterans Health Administration data to identify patients with CRPC who received first-line abiraterone or enzalutamide from 2010 to 2017. Using Poisson regression, we compared outpatient mental health encounters per 100 patient-months on drug between the abiraterone and enzalutamide cohorts adjusting for patient factors (e.g., age). We compared mental health encounters in the year before versus after starting therapy using the McNemar test.

Results

We identified 2902 CRPC patients who received abiraterone (n = 1992) or enzalutamide (n = 9

SUBMITTER: Tsao PA 

PROVIDER: S-EPMC10469813 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature